Provention Bio Inc (PRVB)
8.77
+0.06 (+0.69%)
USD |
NASDAQ |
Jan 27, 16:00
8.76
-0.01 (-0.11%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 764.66M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 157.9% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 215.11 |
Price to Book Value | 5.282 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.1609 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
PR Newswire
01/05 16:01
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
02/24/2023* | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
02/24/2023* | -- | Results | Q4 2022 | -- | -0.32 | -- | |
11/03/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/03/2022 | -- | Results | Q3 2022 | -0.34 | -0.42 | 19.05% | |
08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
08/04/2022 | -- | Results | Q2 2022 | -0.46 | -0.50 | 7.38% | |
05/05/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
05/05/2022 | -- | Results | Q1 2022 | -0.35 | -0.47 | 24.73% |
*Estimated Date/Time
Earnings
Profile
Edit
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101. |
URL | https://www.proventionbio.com |
Investor Relations URL | https://investors.proventionbio.com/ |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Feb. 24, 2023 (est.) |
Last Earnings Release | Nov. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0.00% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
Revenue (TTM) | 2.799M |
Total Expenses (TTM) | 116.65M |
Net Income (TTM) | -106.12M |
Total Assets (Quarterly) | 193.91M |
Total Liabilities (Quarterly) | 49.14M |
Shareholders Equity (Quarterly) | 144.77M |
Cash from Operations (TTM) | -90.89M |
Cash from Investing (TTM) | -74.55M |
Cash from Financing (TTM) | 128.48M |
Ratings
Profile
Edit
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101. |
URL | https://www.proventionbio.com |
Investor Relations URL | https://investors.proventionbio.com/ |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | Feb. 24, 2023 (est.) |
Last Earnings Release | Nov. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
PRVB Tweets |